Cargando…

S131: REGIONAL ASSESSMENT OF THE EXPERIENCES OF HEALTHCARE PROFESSIONALS (HCPS) TREATING PATIENTS WITH SICKLE CELL DISEASE (SCD): THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)

Detalles Bibliográficos
Autores principales:	Osunkwo, I, Andemariam, B, Minniti, C, El Rassi, F, Nur, E, Nero, A, Colombatti, R, de Montalembert, M, Abboud, M, Arlet, J, Jain, S, Jastaniah, W, Pita, M, Trimnell, C, DeBonnett, L, Bailey, T, Rajkovic-Hooley, O, Inusa, B, James, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Oral Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812074/ http://dx.doi.org/10.1097/01.HS9.0000821492.15773.a5

Ejemplares similares

P-010: TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HEALTHCARE PROFESSIONAL (HCP)–PATIENT RELATIONSHIP: HCP OPINIONS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: B., ANDEMARIAM, et al.
Publicado: (2022)

P1467: HEALTHCARE PROFESSIONALS (HCP) OPINIONS ON TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HCP–PATIENT RELATIONSHIP: RESULTS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: Andemariam, B., et al.
Publicado: (2022)

Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY)
por: Osunkwo, Ifeyinwa, et al.
Publicado: (2021)

Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high‐ and low‐ to middle‐income countries for the international Sickle Cell World Assessment Survey
por: Osunkwo, Ifeyinwa, et al.
Publicado: (2022)

S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP)
por: Silva-Pinto, A, et al.
Publicado: (2022)

P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
por: Silva-Pinto, A. C., et al.
Publicado: (2022)

Annual Academy of Sickle Cell and Thalassaemia (ASCAT) conference: a summary of the proceedings
por: Strunk, Crawford, et al.
Publicado: (2020)

P1487: SICKLE CELL HEALTH AWARENESS, PERSPECTIVES AND EXPERIENCES (SHAPE) SURVEY: FINDINGS ON THE BURDEN OF SICKLE CELL DISEASE ON PATIENTS AND THEIR UNMET NEEDS AS REPORTED BY HEALTHCARE PROFESSIONALS
por: de Montalembert, M., et al.
Publicado: (2022)

P-004: HEALTH CARE TRANSITION (HCT) FOR SICKLE CELL DISEASE (SCD) CAN BE STANDARDIZED: RESULTS OF IMPLEMENTING A SCD HCT LEARNING COLLABORATIVE.
por: I., OSUNKWO, et al.
Publicado: (2022)

O-10: SICKLE CELL HEALTH AWARENESS, PERSPECTIVES AND EXPERIENCES (SHAPE) SURVEY: FINDINGS ON THE BURDEN OF SICKLE CELL DISEASE AND UNMET NEEDS AS REPORTED BY PATIENTS AND CAREGIVERS
por: I., ODAME, et al.
Publicado: (2022)

5559749 A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
por: Andemariam, B., et al.
Publicado: (2023)

5612992 SICKLE CELL HEALTH AWARENESS, PERSPECTIVES, AND EXPERIENCES (SHAPE) SURVEY: FINDINGS ON THE BURDEN OF SICKLE CELL DISEASE AND IMPACT ON THE QUALITY OF LIFE OF PATIENTS AND CAREGIVERS IN THE UK
por: Inusa, B.P.D., et al.
Publicado: (2023)

O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
por: A., SILVA-PINTO, et al.
Publicado: (2022)

5572697 TRIALS IN PROGRESS: THE THRIVE STUDIES EVALUATING THE EFFICACY, SAFETY, AND LONG-TERM TREATMENT WITH INCLACUMAB, A P-SELECTIN INHIBITOR, IN PATIENTS WITH SICKLE CELL DISEASE
por: Andemariam, B., et al.
Publicado: (2023)

P1486: TRIALS IN PROGRESS: THE THRIVE STUDIES EVALUATING THE EFFICACY, SAFETY, AND LONG-TERM TREATMENT WITH INCLACUMAB, A P-SELECTIN INHIBITOR, IN PATIENTS WITH SICKLE CELL DISEASE
por: Andemariam, B., et al.
Publicado: (2022)

Sickle cell disease: embedding patient participation into an international conference can transform the role of lived experience
por: Pellegrini, Mariangela, et al.
Publicado: (2023)

Epidemiology of sickle cell disease in Saudi Arabia
por: Jastaniah, Wasil
Publicado: (2011)

The Neonatal Screening Program in Brazil, Focus on Sickle Cell Disease (SCD)
por: Silva-Pinto, Ana C., et al.
Publicado: (2019)

Transition in Sickle Cell Disease (SCD): A German Consensus Recommendation
por: Alashkar, Ferras, et al.
Publicado: (2022)

Neuropsychological assessment, neuroimaging, and neuropsychiatric evaluation in pediatric and adult patients with sickle cell disease (SCD)
por: Edwards, Christopher L, et al.
Publicado: (2007)

The Sickle Cell Disease Functional Assessment (SCD-FA) tool: a feasibility pilot study
por: Oyedeji, Charity I., et al.
Publicado: (2022)

Newborn Screening for Sickle Cell Disease in Europe
por: Daniel, Yvonne, et al.
Publicado: (2019)

Valsartan impedes epinephrine-induced ICAM-4 activation on normal, sickle cell trait and sickle cell disease red blood cells
por: Zhang, Jing, et al.
Publicado: (2019)

S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL
por: Heeney, M, et al.
Publicado: (2022)

Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease
por: Osunkwo, Ifeyinwa, et al.
Publicado: (2020)

Effects of home-based inspiratory muscle training on sickle cell disease (SCD) patients
por: Galvão, Fábio, et al.
Publicado: (2021)

P110: CLINICAL CHARACTERISTICS OF COVID-19 IN SICKLE CELL DISEASE (SCD) PATIENTS
por: Malhan, H, et al.
Publicado: (2022)

Moyamoya Syndrome (MMS) in a Patient With Sickle Cell Disease (SCD) and Protein S Deficiency
por: Saxena, Parima, et al.
Publicado: (2023)

Sickle Cell Disease (SCD) Leading to Pulmonary Arterial Hypertension (PAH) and Cholelithiasis (CL)
por: Chacko, Saran, et al.
Publicado: (2023)

48847 Assessing Transition Outcomes in Sickle Cell Disease (SCD) Prior To Implementation of A Formal Transition Program
por: Sheppard, Sydney, et al.
Publicado: (2021)

P1485: A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
por: Andemariam, B., et al.
Publicado: (2022)

Associations between environmental factors and hospital admissions for sickle cell disease
por: Piel, Frédéric B., et al.
Publicado: (2017)

Chronic organ injuries in children with sickle cell disease
por: Allali, Slimane, et al.
Publicado: (2021)

P1432: PATTERNS OF VOXELOTOR USE IN A MULTICENTER, REAL-WORLD STUDY OF PATIENTS WITH SICKLE CELL DISEASE
por: Andemariam, Biree, et al.
Publicado: (2023)

COVID‐19 and the pulmonary complications of sickle cell disease
por: Sivalingam, Thivya, et al.
Publicado: (2020)

Prognosis of patients with sickle cell disease and COVID-19: a French experience
por: Arlet, Jean-Benoît, et al.
Publicado: (2020)

Early splenectomy in sickle cell disease: another piece of the puzzle
por: Colombatti, Raffaella, et al.
Publicado: (2023)

MR-Augmented Cardiopulmonary Exercise Testing- a proof of concept in Sickle Cell Disease (SCD)
por: Ako, Emmanuel O, et al.
Publicado: (2016)

coreSCD: multi-stakeholder consensus on core outcomes for sickle cell disease clinical trials
por: Tambor, Ellen, et al.
Publicado: (2021)

Intrapartum Management of Sickle Cell Anemia With Rare Antibody and Minimal Blood Availability
por: Dom, Aaron M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t9ngogm786bs08q2dcjibbae35